YMAB - Y-mAbs Therapeutics GAAP EPS of -$0.15 beats by $0.17 revenue of $20.25M beats by $4.7M

2023-05-08 16:03:02 ET

• Y-mAbs Therapeutics press release ( NASDAQ: YMAB ): Q1 GAAP EPS of -$0.15 beats by $0.17 .
• Revenue of $20.25M (+93.0% Y/Y) beats by $4.7M .
• Financial Guidance
• We are updating our full-year 2023 financial guidance, which now reflects:
• Anticipated DANYELZA® net product revenues now expected to be $80-85 million (previously $60-65 million);
• Anticipated operating expenses continues to be expected to be $115-120 million;
• Anticipated total annual cash burn now expected to be $40-50 million (previously $50-55 million); and
• Cash and cash equivalents anticipated to support operations as currently planned into the first quarter of 2026.

For further details see: